NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera's breach of its obligations under the merger agreement between Pfizer and Metsera. Pfizer alleges that the Novo Nordisk offer cannot qualify as a "Superior Company Proposal†u. ...

Key TakeawaysMajor U.S. stock indices closed higher, with the Dow Jones up 0.15%, the S&P 500 gaining 0.31%, and the Nasdaq leading the rally with a 0.70% increase.Pfizer (PFE) received early U.S. Federal Trade Commission (FTC) clearance for its Metsera acquisition, a crucial step forward in its strategy to enter the rapidly growing obesity drug market.Johnson & Johnson (JNJ) submitted an application to the U.S. FDA for Stelara® (ustekinumab) for the treatment of pediatric ulcerative colitis, aiming to expa ...

While many investors focus on semiconductors and AI or the growth sector, one of my Economic Modern Family members has been busy.The Biotech Sector ETF (NASDAQ: IBB), has made new multi-year highs. We cannot say new all-time highs as that was made in 2021 during Covid.However, we can discount that unusual time and safely say the Biotech Sector ETF (IBB) is on a tear and could very well continue. Sign up for our FREE newsletter and receive our best trading ideas and research Leave this field empty ...

Key Takeaways Pfizer will report Q3 2025 earnings before market open, with sales estimated at $16.6 billion.Earnings estimates have fallen to $3.06 per share amid rising costs from recent acquisitions.Higher sales of Vyndaqel, Padcev and Eliquis may have supported growth despite IRA headwinds.Pfizer (PFE) will report its third-quarter 2025 earnings on Nov. 4, before market open. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $16.6 billion and 66 cents per share, respe ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Metsera Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera rallied to a fresh all-time high on Thursday, as investor optimism was bolstered by a billion-dollar bidding war between pharmaceutical giants Pfizer Inc. and Novo Nordisk. In intra-day trading, Metsera Inc. (NASDAQ:MTSR) jumped to a new 52-week high of $66.10 before trimming gains to end the day just up by 22.06 percent at $63.73 apiece. This fo ...

Group 1 - Energy giants Exxon Mobil Corporation and Chevron Corporation are highlighted as leading companies in the pre-market on a busy Friday [1] - AbbVie Inc. is also mentioned as a significant player in the pre-market activity [1] - Upcoming earnings reports include Palantir Technologies Inc. on Monday, followed by major companies like Shopify Inc., Uber Technologies Inc., Pfizer Inc., and Advanced Micro Devices Inc. on Tuesday [1] - Wednesday will feature technology companies such as Applovin Corporation, QUALCOMM Incorporated, and Arm Holdings plc after market [1] - AstraZeneca PLC and ConocoPhillips will report pre-market on Thursday, with KKR & Co. Inc. and Constellation Energy Corporation following on Friday [1]

Core Insights - Novo Nordisk has launched a competitive bid for Metsera, a U.S. obesity biotech firm, challenging Pfizer's existing offer [3] - Novo Nordisk's bid is valued at up to $8.5 billion, surpassing Pfizer's $7.3 billion offer, with a significant upfront payment of $6 billion [3] Company Developments - The competition between Novo Nordisk and Pfizer intensifies in the lucrative weight-loss drug market, where Novo Nordisk already has successful products like Wegovy and Ozempic [3] - Pfizer's stock has shown significant growth in the past, with a notable increase of over 30% in less than two months during 2021, indicating potential for future rallies [4] Financial Metrics - Pfizer's non-COVID operational revenue increased by 7% in Q2 2025, with projected cost reductions of $7.2 billion by 2027 [7] - The obesity market is valued at over $100 billion, highlighting the strategic importance of the Metsera acquisition for Pfizer [7]

Core Insights - Italy's largest bank by assets reported a slight drop in net profit to €2.37 billion as lower interest rates impacted its top line [1] Financial Performance - The bank's net profit decreased to €2.37 billion, indicating a decline compared to previous periods [1] - The decline in profit is attributed to lower interest rates affecting revenue generation [1]

Core Viewpoint - Pfizer may leverage its connections within the Trump administration to counter Novo Nordisk's unexpected bid for Metsera, a U.S. biotech firm focused on obesity treatments [1] Company Analysis - Pfizer is positioned to utilize political connections to influence the outcome of the acquisition bid [1] - Novo Nordisk's bid for Metsera represents a strategic move in the competitive obesity treatment market [1] Industry Context - The obesity treatment sector is experiencing increased M&A activity, highlighting the competitive landscape among pharmaceutical companies [1] - The involvement of political connections in corporate acquisitions underscores the intersection of healthcare and government policy [1]

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently talked about. During the lightning round, when a caller asked about the stock, Cramer commented: “I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to change it. But right now, the drug stocks are just in a world of hurt, and this one continues to be there. You can own it. They gotta figure out something. That yield will protect you for a while, though.” Photo by Spencer ...